ASTRAZENECA PLC

AstraZeneca PLC faces regulatory scrutiny over a breach of the UK’s pharmaceutical code of practice, but its strong financial outlook and favorable market sentiment remain intact, with analysts predicting continued growth and a premium valuation.

AstraZeneca has announced a landmark agreement with the US government to offer discounts of up to 80% off list prices for eligible patients, securing a large and stable revenue stream through Medicaid and positioning the company for future market ac…

AstraZeneca PLC has announced a strategic restructuring of its share-listing framework, moving its ordinary shares from a US ADR program to a direct listing on the NYSE while maintaining its primary London listing, with expected benefits including r…

AstraZeneca PLC’s recent market performance is marked by a 3.22% share decline, a paused £200 million investment in Cambridge, and mixed market reception to its oncology asset Tagrisso, highlighting the company’s need to align optimistic financial …

AstraZeneca has seen a significant decline in short interest, indicating a shift in investor sentiment towards optimism, as the company and its peers prepare for potential interest rate cuts and tariffs.

AstraZeneca has seen a significant decrease in short interest, a drop in bearish sentiment, as the company invests in expanding its US production capacity and participates in a consortium to enhance Sweden’s competitiveness in artificial intelligenc…

AstraZeneca’s stock price is poised for a significant upswing, with 15 out of 18 analysts recommending a buy and an average target price higher than the current market value.

AstraZeneca’s stock price has fluctuated due to market trends and external factors, but analysts remain optimistic about the company’s potential for growth.

AstraZeneca has exceeded expectations with a strong Q2 performance, driven by its cancer medicines and a surge in US sales, with shares rising 1% in early trading.

AstraZeneca reports progress in its research and development efforts, including successful results for its experimental therapy gefurulimab and a strong financial performance expected in the second quarter.